Translational Research
Bridging Preclinical Findings to First-in-Human Decisions
Biomarker strategy, patient stratification models and mechanism-of-action studies designed to give your clinical team the scientific confidence to advance.
Request a study design
Translational Services That Inform Critical Go/No-Go Decisions
We turn preclinical data into a coherent translational narrative — one that speaks to both scientists and clinical development teams.
Biomarker Strategy & Development
End-to-end biomarker programme design: identification, qualification, and assay development for pharmacodynamic, predictive and safety biomarkers aligned to your clinical endpoints.
Request protocol →Patient Stratification Models
Genomic, proteomic and histological profiling to identify responder populations. Patient-derived xenograft (PDX) panels and co-clinical trial designs to support precision medicine strategies.
Request protocol →Mechanism-of-Action Studies
Hypothesis-driven mechanistic experiments using genetic knockdown, pharmacological inhibition and pathway analysis to establish the causal link between target modulation and efficacy.
Request protocol →Translational PK/PD Modelling
Allometric scaling, species translation and human dose prediction based on preclinical PK/PD relationships. IVIVE modelling to support first-in-human starting dose selection.
Request protocol →Regulatory-Ready Reporting
IND/CTA briefing documents, preclinical summary sections and integrated study reports structured to FDA, EMA and ICH requirements. Full data traceability and audit trail.
Request protocol →Scientific Partnership
Embedded scientific advisory support for biotechs and academic spin-outs. Study director involvement from concept to report, providing continuity across the entire preclinical programme.
Request protocol →Therapeutic Focus Areas
Our translational team has deep expertise in the disease areas where preclinical-to-clinical translation is most challenging — and most consequential.
Oncology
Translational packages for solid tumours and haematological malignancies. Biomarker-stratified efficacy studies, resistance mechanism characterisation and co-clinical PDX trial designs.
- ctDNA and circulating tumour cell analysis
- Tumour mutational burden profiling
- Immuno-oncology biomarker panels
- Resistance mechanism sequencing
CNS & Neurodegeneration
Fluid and tissue biomarker development for neurological programmes where the translational gap between rodent models and human disease is a critical development risk.
- CSF and plasma biomarker assays
- Neuroinflammation marker panels
- Synaptic integrity endpoints
- Neuroimaging correlates
Inflammation & Autoimmunity
Translational biomarker programmes for inflammatory and autoimmune diseases — linking preclinical mechanistic data to clinically measurable endpoints and patient selection strategies.
- Serum and synovial fluid biomarkers
- Immune cell phenotyping panels
- Patient stratification by MoA
- Companion diagnostic development
Analytical Capabilities
A broad analytical platform enables us to interrogate the biology at the molecular, cellular and tissue level within a single integrated programme.
Genomics & Transcriptomics
Bulk and single-cell RNA-seq, qPCR gene expression panels, whole-exome sequencing and targeted amplicon panels for mutation and resistance profiling.
Proteomics & Immunoassays
Multiplex Luminex, ELISA, proximity extension assay (PEA/Olink) and targeted proteomics by LC-MS/MS for serum, plasma, CSF and tissue lysates.
Histology & Imaging
FFPE IHC/IF with digital pathology image analysis, multiplex immunofluorescence (mIF) for spatial biomarker co-localisation and in vivo IVIS bioluminescence imaging.
Flow Cytometry
Multi-parameter immunophenotyping, intracellular cytokine staining and phospho-flow for signalling pathway analysis in tumour, blood and lymphoid tissue samples.
From Scientific Question to Clinical Evidence Package
A structured process that turns a preclinical dataset into a compelling translational story for your development team and investors.
Translational Strategy Workshop
We work with your scientific and clinical leadership to map the translational gaps in your programme, define the key biological questions and design a biomarker strategy that addresses them systematically.
Integrated Study Execution
Mechanistic in vivo studies, biomarker assay development and analytical platform work run in parallel under unified project management, with regular data reviews and protocol adjustments as needed.
Evidence Package & Narrative
A comprehensive translational evidence package including integrated data interpretation, human dose projections and a scientific narrative ready for IND/CTA submission, investor presentations or partnering discussions.
Translational Impact by the Numbers
Ready to Build Your Translational Package?
Tell us about your molecule and the clinical question you need to answer. Our translational team will propose a biomarker strategy within 48 hours.
Discuss your project